Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,497 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-small Cell Lung Cancer (NSCLC) Clear all
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3174998, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions
Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
174
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tissue Collection
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced May 21, 2026, 5:35 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Squamous Tumors
Interventions
ABBV-711, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABT-751
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
17
States / cities
Miami, Florida • New Port Richey, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
HFB200301, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
Radiation · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer
Interventions
CKD-703
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
19 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, RG1507, erlotinib [Tarceva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Beverly Hills, California • New Port Richey, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions
ONM-100
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Interventions
Zanidatamab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
Docetaxel, Vandetanib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Lenvatinib, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
28
States / cities
Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced May 21, 2026, 5:35 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Lorlatinib, Cisplatin or Carboplatin, Pemetrexed
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Asheville, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06664178
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced May 21, 2026, 5:35 PM EDT